Current Headlines

31. Cerevel Therapeutics And Cyclica Announce Research Collaboration To Use Artificial Intelligence To Accelerate Discovery Of Novel Medicines In Neuroscience 7/27/2020

    Cerevel Therapeutics, a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, and Cyclica, whose AI-augmented, integrated platform enables multi-objective, polypharmacology-informed design of drug molecules, today announced a research collaboration aimed at accelerating the discovery of novel medicines for neuroscience diseases

32. Pharmaxis Submits Investigational New Drug (IND) Application For The Treatment Of Myelofibrosis 7/23/2020

    Pharmaceutical research company Pharmaxis Ltd, the leading developer of therapeutics targeting lysyl oxidase enzymes to treat fibrosis and cancer, announced it has submitted an Investigational New Drug (IND) application to the US Food and Drug Administration (FDA) for a planned phase 1/2 study of PXS‐5505 for the treatment of myelofibrosis

33. Cobomarsen Receives Orphan Drug Designation From The U.S. FDA For The Treatment Of T-cell Lymphoma 7/23/2020

    miRagen Therapeutics, Inc. (NASDAQ: MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, today announced that the Food & Drug Administration (FDA) has granted orphan drug designation to cobomarsen, for the treatment of T-cell lymphoma

34. Curi Bio Acquires Dana Solutions 7/23/2020

    Curi Bio, a leading developer of human iPSC-based platforms for drug discovery, has acquired Dana Solutions, a pioneer in the application of artificial intelligence and machine learning to in vitro cell-based assays

35. Lupin Receives Tentative Approval For Empagliflozin And Linagliptin Tablets 7/23/2020

    Pharma major Lupin Limited (Lupin) announced that it has received tentative approval for its Empagliflozin and Linagliptin Tablets, 10 mg/5 mg and 25 mg/5 mg, from the United States Food and Drug Administration (U.S. FDA) to market a generic version of Glyxambi Tablets, 10 mg/5 mg and 25 mg/5 mg, of Boehringer Ingelheim Pharmaceuticals, Inc

36. New Cell Profiling Method Could Speed TB Drug Discovery 7/23/2020

    A new technology that combines high throughput imaging and machine learning could speed discovery of drugs to fight tuberculosis, which for generations has killed more people worldwide than any other disease caused by a single agent—4,000 people every day

37. Alzheimer's Drug Discovery Foundation (ADDF) Announces New Biobank Sharing Program To Accelerate Alzheimer's Disease Biomarker Research 7/22/2020

    The Alzheimer's Drug Discovery Foundation (ADDF) has partnered with leading pharmaceutical companies to create one of the largest biobank sharing programs including blood and cerebral spinal fluid specimens from Alzheimer's disease patients who participated in earlier clinical trials

38. CalciMedica And EpiPharma Enter Into Research Collaboration To Discover And Develop CRAC Channel Inhibitor Therapies 7/21/2020

    CalciMedica, a clinical-stage biotechnology company targeting calcium release-activated calcium (CRAC) channels for the treatment of acute and severe inflammatory diseases, and EpiPharma, a bio-pharmaceutical services and drug development company, today announced that they have entered into a collaboration agreement to use EpiPharma’s state-of-the-art Pre-clinical Drug Testing and Diagnostics Laboratory Platform to accelerate the discovery and development of CalciMedica’s CRAC channel inhibitor novel drug pipeline

39. AbCellera Announces Agreement With Alloy Therapeutics To Integrate Access To ATX-Gx Humanized Mice Platform For Antibody Discovery Programs 7/21/2020

    AbCellera today announced that it has entered into an agreement with Alloy Therapeutics to use the ATX-Gx humanized mice platform to enable best-in-class in vivo human antibody discovery for its partner programs

40. National Institutes Of Health Awards Boragen $300,500 Grant For Antimalarial Drug Discovery 7/21/2020

    Boragen, Inc., a world-leading boron-based discovery platform company, has been awarded a $300,500 Phase I Small Business Innovation Research (SBIR) grant from the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH)